TrialSafety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects
Trial details
- Registry ID
- NCT04802837
- Phase
- Phase 3
SMMT
Summit Therapeutics
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
5Trials in this database
5Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent SubjectsNCT04802837 | Summit Therapeutics | Phase 3 | Terminated | 2021-09-17Actual |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsNCT05899608 | Summit Therapeutics | Phase 3 | Recruiting | 2028-12-31Estimated |
| Phase III Study of AK112 for NSCLC PatientsNCT06396065 | Summit Therapeutics | Phase 3 | Active not recruiting | 2025-04-12Actual |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1NCT06767514 | Summit Therapeutics | Phase 3 | Recruiting | 2028-04Estimated |
| Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal CancerNCT07228832 | Summit Therapeutics | Phase 3 | Recruiting | 2028-05-31Estimated |
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Trial details
- Registry ID
- NCT05899608
- Phase
- Phase 3
Phase III Study of AK112 for NSCLC Patients
Trial details
- Registry ID
- NCT06396065
- Phase
- Phase 3
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Trial details
- Registry ID
- NCT06767514
- Phase
- Phase 3
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Trial details
- Registry ID
- NCT07228832
- Phase
- Phase 3
Latest recorded trial changes
Phase III Study of AK112 for NSCLC Patients
NCT06396065 · Summit Therapeutics
Participant count type changed
− Before
Estimated
+ After
Actual
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
31 Dec 2025
+ After
12 Apr 2025
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608 · Summit Therapeutics
Planned enrollment increased by 520 participants
− Before
1080 participants (planned)
+ After
1600 participants (planned)
Primary completion date changed
− Before
31 Dec 2027
+ After
31 Dec 2028